The effect of 3h-azido-3h-deoxythymidine (AZT) on in vitro infection of peripheral blood mononuclear cells (PBMCs) isolated from normal adult individuals with human T cell leukaemia/lymphoma virus type I (HTLV-I) was evaluated. Different PBMC samples were exposed to HTLV-I by cocultivation with MT-2 (a chronically infected cell line) in the presence of 20 U/ml of human recombinant interleukin 2 (IL-2) and graded concentrations of AZT. Control and drug-treated cultures, of both infected and uninfected PBMCs, were then grown for several weeks and monitored for virological and immunological parameters. The results showed a concentrationdependent anti-proliferative effect of AZT in both infected and non-infected cultures. Production of both proviral DNA and viral RNA was inhibited not
Introduction
Antiretroviral therapy has been extensively investigated in the past decade. The main objective in the study of antiviral drugs is to develop compounds which are minimally toxic for normal cells and highly specific in blocking virus replication. 3h-Azido-3h-deoxythymidine (AZT) is an analogue of thymidine in which the 3h-hydroxyl group is replaced by an azido group. It is known that this compound is phosphorylated intracellularly by nucleoside and nucleotide kinases to its 5h-triphosphate, and that in this form it inhibits retroviral reverse transcriptase (Cooney et al., 1987) . Thus, AZT acts by competing with 2h-deoxyribonucleotides in the extension of the viral DNA strand. This compound remains the most Author for correspondence : Beatrice Macchi.
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only at the higher concentrations of AZT (8 µM and 32 µM) but also at concentrations as low as 0n1-2 µM. These results were confirmed by PCR and by flow cytometry analysis for the viral core protein p19. Moreover, treatment with AZT resulted in a decreased expression of CD25 in cultures exposed to HTLV-I as well as in non-infected PBMCs. On the other hand, HLA-DR was down-regulated to a greater extent in drug-treated, virus-exposed cultures in comparison with those not infected. No evidence of the antiviral activity of AZT was observed in PBMC cultures already infected by HTLV-I or in MT-2 cells. These findings demonstrate that treatment with AZT, when given at the time of infection with HTLV-I, has a marked protective effect on PBMCs.
common agent prescribed in the treatment of human immunodeficiency virus (HIV) infection in AIDS patients (Fischl et al., 1987 ; Mitsuya et al., 1985) .
Human T cell leukaemia\lymphoma virus type I (HTLV-I) is associated with adult T cell leukaemia (ATL) (Yoshida et al., 1982) , which is endemic in south-west Japan, and also with cutaneous T cell lymphomas in the United States and the West Indies (Poiesez et al., 1980) . More recently, HTLV-I was also found to be associated with neurological syndromes, particularly HTLV-I associated human myelopathies in Japan and tropical spastic paraparesis in South America (Osame et al., 1986 ; Jacobson et al., 1988) , in uveitis and arthropathies (Sagawa et al., 1995 ; Nishioka et al., 1989) . In vivo, virus transmission can be either horizontal and\or vertical, and usually results from blood exchange (Okochi et al., 1984 ; Osame et al., 1986 b) or breast feeding (from mother to child) (Hino et al., 1985) . In vitro, HTLV-I infection can be transmitted to adult and cord blood cells (Miyoshi et al., 1981 ; Macchi et al., 1987) or to other cell types (Hoxie et al., 1984 ; Macchi et al., 1992) mainly by cell-to-cell contact. In long-term culture, HTLV-I, in contrast to HIV, can induce immortalization of infected cells (Kimata & Ratner, 1991 ; Sodroski, 1992) . T cells infected and selectively expanded in response to HTLV-I infection are predominantly CD4 + and show an increased expression of the human recombinant interleukin 2 (IL-2) receptor α-chain (Depper et al., 1984) . The induction of longterm growth of HTLV-I infected cells could be a useful model for studying the effect of drugs during the virus transmission stage and also in the immortalization phase. Nevertheless, there are a limited number of studies showing that it is possible to modulate HTLV-I infection in vitro. Our previous investigations showed that α-and β-interferons (IFN) were partially able to protect cord and adult blood from HTLV-I transmission (Macchi et al., 1990 (Macchi et al., , 1993 . Other compounds such as prostaglandin A (PGA) and PGJ (Lacal et al., 1995) , suramin (Pesce et al., 1987) and the natural compound kelletinin A (Silvestri et al., 1995) were shown to inhibit HTLV-I infection through different mechanisms. Some reports have shown that AZT is effective when administered in vivo in rabbits (Isono et al., 1990) , or in combination with IFN-α in ATL patients (Gill et al., 1995 ; Hermine et al., 1995) . Moreover, the protective effect of AZT on HTLV-I infection in vitro has been shown using antigen-specific cell clones (Matsushita et al., 1987) . However, the protective effect in vitro of AZT toward HTLV-I infection of primary cultures of normal human lymphocytes has not been investigated. In order to define the antiviral activity of AZT in HTLV-I infection, we have analysed the protective effect of AZT on virus infection in bulk cultures of mononuclear cells isolated from the peripheral blood of normal donors. Different concentrations of AZT were assessed for antiviral activity, as well as for effects on cell proliferation and growth. Furthermore, since AZT can modulate some immune functions (Heagy et al., 1991) , we investigated the interference of AZT with the expression of some activation markers on cells exposed to HTLV-I.
Methods
In vitro infection with HTLV-I and AZT treatment. Human peripheral blood was obtained from normal, HIV-hepatitis B\C-negative adult donors. Fresh peripheral blood mononuclear cells (PBMCs) were separated by Ficoll-Hypaque density gradient (Pharmacia). The cells were then washed twice in RPMI 1640 medium (Gibco).
HTLV-I was transmitted to PBMCs by coculturing with lethally irradiated (120 Gy, from a caesium gamma cell irradiator 1000, Canada Atomic Energy) MT-2 cells, at a 5 : 1 ratio. MT-2 is a chronically infected cell line derived from cord blood cocultivated with irradiated HTLV-I positive cells collected from an ATL patient (Miyoshi et al., 1981) . HTLV-I infected cell lines grown in the presence of IL-2 were designated PBXXMT, where XX identifies the donor. Cocultures were maintained in six-well plates, at a concentration of 10' cells\ml, in medium containing 20 U\ml of IL-2 (Hoffman La Roche), in the presence or absence of AZT (kindly supplied by Glaxo Wellcome R & D, Beckenham, UK). Cultures were passaged weekly and cell growth was monitored by evaluating numbers of living cells using a trypan blue dye exclusion test. Usually AZT, at concentrations of 0n1, 0n5, 2, 8 and 32 µM, was added at the onset of the culture and then at half concentrations 3, 7 and 10 days postinfection (p.i.). For calculation of IC &! , concentrations ranging from 0n007 µM to 32 µM were used. In some experiments, AZT was added to the cultures for the first time 14 days p.i., and then at half concentration 17, 21 and 24 days p.i. ; cultures were checked for virus 2 weeks after the first addition of AZT. In other experiments, MT-2 cells were diluted at 1i10' cells\ml and treated with AZT at concentrations of 0n5, 8 and 32 µM. The drug was then added at half concentration after 3, 7 and 10 days, and MT-2 cells were checked for the presence of virus 4 days after the last addition of AZT.
Proliferation assay. Proliferation of the cultures was measured by a [$H]thymidine (Amersham) uptake assay. Briefly, PBMCs were distributed in 96-well round bottomed plates at 1i10& cells per well in the absence of stimuli. Cultures were incubated for 3, 7 and 10 days p.i. at 37 mC, at which times the cells were pulsed with 1 µCi [$H]thymidine per well, following each AZT treatment. After overnight incubation, pulsed cells were harvested onto glass fibre filters with an automatic cell harvester (Skatron). Filters were air-dried and then processed through a β-scintillation counter (model 1214, LKB, Wallac). Radioactivity was measured and incorporated [$H]thymidine expressed as c.p.m.
Detection of viral DNA and RNA by dot blot analysis. The amount of proviral DNA was determined using a sensitive ' dot blot ' hybridization assay as previously described (Macchi et al., 1993) . Briefly, serial dilutions of cells were spotted onto nitrocellulose membrane filters (Schleicher and Schuell). The filters were denatured in 0n5 M NaOH and fixed in 1n5 M NaCl. They were then neutralized in 0n2 M Tris-HCl and 2i SSC (0n3 M sodium citrate, 3 M NaCl, pH 7n0), dried and baked at 80 mC for 2 h. The amount of virus transcript was evaluated by spotting serial dilutions of cells as above. The filters were then fixed in 3 % NaCl, 10 mM NaH # PO % , 40 mM Na # HPO % , 1 % glutaraldehyde (Merck) and digested with proteolytic buffer (50 mM EDTA, 0n1 M Tris-HCl, pH 8 and proteinase K (20 µg\ml, Sigma). DNA and RNA were hybridized with the SstI-SstI fragment of HTLV-I (8n3 kb) digested from the MT-2 plasmid (kindly provided by R. C. Gallo, NIH, Bethesda, Md., USA), or with the 0n9 kb EcoRI fragment of the human glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene (a generous gift from Dalla Favera, Department of Pathology, Columbia University, New York, NY, USA). Nitrocellulose filters were hybridized for about 20 h in 10i Denhardt's solution, 4i SET and 0n1 % SDS. The probe was radiolabelled with [α-$#P]dCTP by a random primers procedure, and the filters were exposed to Kodak XAR-5 films for autoradiography.
Extraction of genomic DNA and PCR analysis. DNA was incubated with proteinase K at 37 mC and extracted in phenolchloroform-isoamyl alcohol (50 : 49 : 1), according to standard procedures (Sambrook et al., 1992) . One µg of DNA was used as template and was amplified in a standard PCR reaction mix : 1i PCR buffer, 0n2 mM dNTPs, 1n25 U of Taq polymerase (Boehringer Mannheim), 0n5 µM primers [pair-specific for the POL region of HTLV-I (SK54, SK55 ; PerkinElmer), or for the β-globin gene (5h ACACAACTGTGTTCACTAGC 3h, 5h CAACTTCATCCACGTTCACC 3h ; Hoffman et al., 1992) ]. Samples were subjected to 30 cycles of PCR amplification, each cycle consisting of 30 s at 94 mC, 30 s at 55 mC and 45 s at 72 mC on a Cetus DNA thermal cycler 2400 (Perkin-Elmer). After the last cycle, samples were further incubated at 72 mC for 7 min, to ensure completion of the final extension step.
Amplified DNA products were analysed by liquid hybridization and probed using specific $#P-end-labelled oligonucleotides. The oligonucleotides used were as follows ; SK56 to detect the POL region, and 5h
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CTCCTGAGGAGAAGTCTGC 3h to detect β-globin. The samples were denatured for 5 min at 95 mC and annealed at 55 mC for 15 min. A running buffer was added to the samples and they were loaded onto an 8 % polyacrylamide gel. After electrophoresis the gel was dried and exposed for autoradiography.
Detection of HTLV-I p19 expression by flow cytometry. Expression of the viral core protein p19 was evaluated by FACS analysis, as previously described (Macchi et al., 1991) . Briefly, cells were washed in PBS, resuspended in 200 µl of PBS and fixed in 70 % ethanol for 30 min at 4 mC. Infected and uninfected PBMCs were then washed twice in PBS, and diluted to 1i 10' cells\ml. Cells were incubated with a murine monoclonal antibody (MAb) against the viral Gag protein p19 (kindly provided by M. Robert-Guroff, NIH), for 30 min at 4 mC. The samples were than washed and incubated with fluorescein isothiocyanate (FITC)-conjugated F(Ab) # fragment of goat anti-mouse IgG. MT-2 cells were used as a positive control and a negative control was set by incubating cells with FITC-conjugated goat anti-mouse IgG only. Flow cytometry analysis was done with a FACScan (Becton-Dickinson). Fixed cells were gated by forward and single-angle scatter, excluding debris, cell aggregates and dead cells. The percentage of positive cells for each sample was calculated by subtracting the background percentage positivity obtained in a corresponding negative control.
Phenotype analyses by flow cytometry. Cultures were analysed for the expression of CD4, CD8, HLA-DR and CD25 surface molecules. The MAbs used were phycoerythrin (PE)-conjugated CD4, CD25, and FITC-conjugated CD8, HLA-DR (Becton-Dickinson), for a two-colour analysis. Staining was done at 4 mC for 30 min. After treatment the cells were washed twice in PBS, containing 0n02 % sodium azide, and used immediately. Flow cytometry analysis was done with a FACScan (Becton-Dickinson). For the analysis, markers were set to indicate boundaries limiting 98-99 % of the background events in the respective control sample. Background percentage positivity was subtracted from experimental samples. Live lymphoid cells were gated to exclude debris, dead cells, giant cells and cell aggregates.
Data analysis and calculation of IC 50 . The mean values of samples were compared by unpaired or paired (where specified) Student's t-test and the P value of 0n05 was considered statistically significant.
Values of IC
&! were calculated according to the best-fit curve (y value vs log x, where y is the value of the examined function and x is the drug concentration).
Results
Effect of AZT on proliferation and growth of HTLV-I infected and uninfected PBMCs
PBMCs were cocultivated with MT-2 and after 3, 7 and 10 days of exposure to the virus, spontaneous cell proliferation was assayed by [$H]thymidine uptake. Fig. 1 (a) shows the results obtained in the culture designated PB54MT. Experiments performed on cultures with cells obtained from three other donors gave similar results. At 3 days p.i., AZT concentrations of 8 µM and 32 µM caused 60 % and 90 % inhibition of thymidine uptake, respectively, in infected cultures compared with untreated cultures (P l 0n0005 and P l 0n0001, respectively). Inhibition of the proliferative capacity of PB54MT treated with high concentrations of AZT was statistically significant at 7 and 10 days p.i. also, although the proliferative rate of untreated PB54MT diminished during the culture. Low concentrations of AZT (0n5 µM and 2 µM) Statistical analysis by Student's t-test of the comparison against the corresponding untreated controls gave the following results. Day 3, 0n5 µM AZT, P l 0n0171 ; 2 µM AZT, P l 0n0170 ; 8 µM AZT, P l 0n0005 ; 32 µM AZT, P l 0n0001. Day 7, 2 µM AZT, P l 0n0016 ; 8 µM AZT, P l 0n0023 ; 32 µM AZT, P 0n0001. Day 10, 8 µM AZT, P l 0n0159 ; 32 µM AZT, P l 0n0014. No other comparisons were significant. Values are from one representative experiment of four performed. reduced thymidine uptake of PB54MT by approximately 35 % with respect to the control 3 days p.i. (P l 0n0171 and P l 0n0170, respectively), whereas 0n1 µM AZT did not show any significant effect. Proliferation in cultures not exposed to MT-2 was remarkably low in comparison with that obtained in cultures cocultivated with the chronically infected donor cell line (Fig. 1 b) . In addition, AZT treatment reduced the proliferation of uninfected cultures, with respect to the untreated control, only at high concentrations and particularly at 3 days p.i. (8 µM, P l 0n0021 ; 32 µM, P 0n0001). Actually, proliferation of uninfected PBMCs, grown in the presence of low concentrations of AZT (0n1-2 µM), did not differ significantly from that of untreated controls. In order to investigate the effect of AZT on long-term cultures, growth of HTLV-I infected and uninfected PBMCs, evaluated by monitoring living cell counts weekly, was examined over 6 weeks. The representative results obtained from a single donor, PB54 (non-infected), are illustrated (Fig. 2) . Virus-exposed cultures (Fig. 2 a-e) , independent of the amount of AZT used, showed an initial dramatic cell expansion. After 6 weeks, the number of viable cells in infected cultures treated with concentrations of AZT ranging from 0n5 µM to 32 µM had rapidly decreased (Fig. 2 b-e) , and all cultures eventually died, whereas, the growth of PB54MT treated with 0n1 µM AZT was similar to that observed in the untreated control (Fig.  2 a) . Statistical comparison of cumulative values obtained in cultures from all of the four donors, in the paired t-test, showed a significant decrease in the number of living cells in AZTtreated infected cultures with respect to untreated infected counterparts (0n5 µM, P l 0n0397 ; 2 µM, P l 0n0326 ; 8 µM, P l 0n0153 ; 32 µM, P l 0n0101), with the exception of 0n1 µM, at 6 weeks p.i. In fact, only infected untreated cells and infected cells treated with 0n1 µM AZT were kept in culture until 12 weeks p.i., when all the experiments were stopped. However, in the late phase of culture, cells treated with 0n1 µM AZT grew at a very low rate. Conversely, infected counterparts which were left untreated showed the characteristic growth of cell lines prone to immortalization (data not shown). The number of living cells in cultures not exposed to HTLV-I and in the presence of only IL-2 as an exogenous stimulus ( Fig.  2 f-j) , showed a similar pattern of decline in untreated as well as in AZT-treated cells, at all AZT concentrations used. Comparable results were obtained with another three cultures subjected to similar experimental conditions.
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Effect of AZT on HTLV-I infection detected by DNA or RNA dot blot assays and by PCR
The presence of HTLV-I proviral DNA in infected PBMCs was assessed following direct lysis of the cells. Table 1 shows the results of a comparative densitometric analysis of DNA in the four cultures, following treatment with 0n1-32 µM AZT 3 weeks p.i. The results are expressed as a percentage of proviral DNA inhibition. Cultures were found to be markedly protected at all concentrations of AZT tested, with the exception of 0n1 µM AZT, which provided full protection in only one case (PB50MT). Table 2 shows similar results of RNA analysis, with a protective effect of AZT that seems to be even more dramatic. Further results can be seen in Fig. 3 (a) , which shows the dot blot analysis of DNA and RNA in serial dilutions of virus-exposed cells from PB54MT, 7 weeks p.i. The AZT persistently inhibits the emergence of infected cells at a late phase of culture. Where filters were hybridized with a probe specific for the housekeeping gene GAPDH, no differences were detected among controls and cells treated with different concentrations of AZT (data not shown). Similar results were obtained in three other cultures from different donors. On the other hand, treatment with AZT of already infected PBMCs or of MT-2 cells, did not result in any inhibition of viral DNA, as determined by dot blot analysis (data not shown). In order to investigate whether the inhibition of proviral DNA was reproducible using a different assay, genomic DNA, extracted from PB59MT (one of the four cultures tested in the dot blot analysis) was analysed 3 weeks p.i. by PCR. The results in Fig.  3 b showed that addition of 0n5, 8 and 32 µM AZT to the cultures caused complete inhibition of proviral DNA compared with the untreated control. In a few cultures, from the same donor, AZT was added 2 weeks p.i. In this case the compound was not effective (Fig. 3 b) . Similarly, AZT did not affect proviral DNA when added to the MT-2 cells (Fig. 3 b) . Amplification with primers specific for β-globin revealed that comparable amounts of DNA were analysed.
Expression of p19 in AZT-treated PBMCs exposed to HTLV-I
The effect of AZT on the expression of viral proteins was assessed by analysing the presence of the viral Gag protein p19 in the same four cultures assayed for the presence of viral DNA and viral RNA, 6 weeks p.i. At the earlier culture times tested, the proportion of p19 positive cells was too low to demonstrate differences between untreated or AZT treated infected cultures (data not shown). Fig. 4 a shows that when PB54MT cells were exposed to HTLV-I in the absence of AZT, 25n8 % of the cells expressed p19. In the presence of 32 µM AZT a remarkable decrease of positive cells was observed (99 % inhibition, Fig. 4 c) . AZT at a concentration of 8 µM inhibited viral Gag protein p19 production as did 32 µM AZT, whereas 0n5 µM AZT inhibited the expression of p19 by 93 % (Fig. 4 d-e) . Similar results were obtained in cultures from the other three donors tested.
Comparison of anti-proliferative and antiviral activity of AZT by determining IC 50 values
Considering the above results, it was interesting to compare quantitatively the anti-proliferative and the antiviral effects exerted by AZT in cultures infected by HTLV-I. Thus, in a further experiment we compared IC &! values obtained in the Table 3 . Comparison of anti-proliferative and antiviral activity of AZT Cultures of PBMCs isolated from a single donor, designated PB61 (non-infected), were exposed to HTLV-I and left untreated or treated at the onset of the culture with concentrations of AZT ranging from 0n031 µM to 32 µM for the anti-proliferative assay or from 0n008 µM to 8 µM for the antiviral assays. The proliferative assay was performed 3 days p.i. Expression of Gag P19 protein was analysed by flow cytometry 4 weeks p.i. and DNA\RNA dot blot assays were performed 3 weeks p.i. Results are expressed as mean IC &! values pSE from quadruplicate samples in the anti-proliferative assay and from triplicate samples in the antiviral assays, respectively. IC &! values were calculated using data derived from control cultures and cultures treated with six different concentrations of AZT (see Methods). The Pearson coefficient for all regression lines used for a single IC &! evaluation was not less than 0n90.
Assay IC 50 value
Proliferative assay 2n0p0n4 P19 expression 0n08p0n01 DNA dot blot 0n03p0n01 RNA dot blot 0n01p0n00
proliferative assay, in p19 expression analysis and in RNA\ DNA dot blot assays. Cultures of PBMCs isolated from a single donor, designated PB61 (non-infected), were exposed to HTLV-I and were either AZT treated or left untreated from the onset of culture. In order to obtain a best-fit curve, we used a greater number of samples and lower concentrations of AZT than in earlier experiments. We chose AZT concentrations of 0n031, 0n125, 0n5, 2, 8 and 32 µM for testing the antiproliferative activity and AZT concentrations of 0n008, 0n031, 0n125, 0n5, 2 and 8 µM for testing the antiviral effect. The proliferative assays and DNA\RNA dot blot assays were performed 3 days and 3 weeks p.i., respectively. The expression of Gag p19 protein was analysed 4 weeks p.i. Results reported in Table 3 show that IC &! values obtained in the different antiviral assays were substantially lower than those obtained in the anti-proliferative assays.
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Expression of cell surface molecules
Cultures treated with different amounts of AZT were analysed 3 weeks p.i. for the expression of CD25 and HLA-DR markers (Fig. 5) . Cultures exposed to HTLV-I in the absence of AZT showed 70 % positive cells for CD25 (Fig. 5 a) . Treatment of PB59MT with 8 µM and 32 µM AZT caused 30 % and 56 % inhibition of CD25 expression, respectively, whereas 0n5 µM AZT did not have any effect. Moreover, 32 µM AZT also down-regulated CD25 in uninfected cultures, resulting in 40 % inhibition of expression of this molecule (Fig. 5 e-f) . Conversely, HLA-DR was down-regulated in virus-exposed cells to the same extent in the presence of 32 µM AZT as with 8 µM and 0n5 µM AZT (50 % inhibition, Fig. 5 b-d ). This effect was not observed in unexposed cultures (Fig. 5 e-f ). The expression of CD4 and CD8 molecules was not affected by treatment with AZT (data not shown).
Discussion
Our results demonstrate that AZT is able to protect mononuclear cells isolated from different donors from HTLV-I infection in vitro. Data regarding the protective effect of AZT toward HTLV-I infection have been controversial. This retrovirus was reported to be resistant to the effect of AZT, as determined by assaying inhibition of syncytium formation in MOLT-4 cells cocultivated with an HTLV-I-producing cell line (Tochikura et al., 1989) . In contrast, it was also reported that antigen-specific clones from normal donors were protected from HTLV-I infection following treatment with 3, 9 or 27 µM AZT (Matsushita et al., 1987) . However, the infected clones failed to grow in the presence of 9 µM or 27 µM of AZT after 2 weeks in culture. Other studies claim that AZT used at antiviral concentrations can be toxic to human or animal cell lines (Chi & Duesberg, 1995) . One new aspect of the present study is that for the first time the protective effect of AZT on HTLV-I infection was investigated using unstimulated mono-B. Macchi and others B. Macchi and others nuclear cells isolated from normal donors as an experimental model. In fact, this model appears more suitable for simulating in vitro treatment of a naturally occurring infection. Actually, in vivo infection with HTLV-I would normally result from cell-tocell contact (Franchini, 1995) . An additional new aspect of the present investigation was the use of low concentrations of AZT (2 µM or less). In our hands, AZT concentrations above 8 µM were found to be remarkably anti-proliferative for target cells in both infected and non-infected cultures. Conversely, concentrations in the range of 0n5-2 µM which had limited anti-proliferative effects, were still able to protect cultures from infection. AZT inhibited cell proliferation in infected cultures to a greater extent than in uninfected counterparts. This may be at least partly explained if cell-to-cell contact during virus transmission contributes to a high rate of cell proliferation. If this is so AZT could exhibit a more significant suppressive activity in comparison with that found in uninfected controls kept in IL-2. However, high inhibition of proliferation by AZT in cells exposed to HTLV-I could also be ascribed to the strong effect on proviral DNA synthesis and consequent lack of a permanent stimulus to growth. Our experimental model was set up to evaluate the protective effect of AZT in long-term cultures, after repeated treatments at an early stage of the culture. Molecular results, using dot blot analysis of cell lysates as a fast screening test, have shown that AZT exerted a longlasting inhibitory effect on the synthesis of proviral DNA, when added at the onset of the culture. Because of possible drawbacks of the dot blot assay resulting from non-specific hybridization of the sample with the HTLV-I fragment or low sensitivity, PCR analysis was performed. This confirmed that the protective effect of AZT was complete. Our data also suggest that the prevention of immortalization by AZT, shown by a decrease in the cell number and death of the cultures, was due to inhibition of proviral DNA at the onset of the culture, that is, in the acute phase of the infection. When AZT was added 2 weeks p.i., it was completely inactive as an antiviral. Similarly, it showed no antiviral activity on an established infected cell line, suggesting that inhibition of virus infection by AZT in PBMCs did not result from any effect of the drug on the virus donor cell line, MT-2. Nevertheless, particularly at high concentrations, AZT had a sustained antiproliferative effect, and a protective effect against HTLV-I infection (data not shown). Taken together these data, and those obtained from comparative IC &! values, suggest that the anti-proliferative and the antiviral effects of AZT represent two distinct phenomena attributable to different mechanisms, and indicate that protection afforded by AZT against HTLV-I infection even at high concentrations is not due to its cytostatic or cytotoxic effect toward target cells.
Another aspect that needs to be pointed out is that the long-term response to AZT, evaluated as its ability to prevent immortalization, was not linearly dose-dependent, but showed a threshold-like effect. When concentrations 5-10 times lower than 0n1 µM were used, no protection occurred, indicating that 0n1 µM AZT is a concentration threshold below which the compound is inactive in vitro (data not shown). It has been shown that AZT can induce cell resistance to its antiviral effect in HIV infection (Dianzani et al., 1994) . In our model of longterm culture, spontaneous outgrowth of infected cells was not observed at concentrations higher than 0n1 µM. Therefore, the partial protection at a concentration of 0n1 µM seems simply attributable to the fact that at this concentration not all target cells received a drug dose sufficient to block all DNA synthesis, rather than to a drug-resistance phenomenon. A series of studies have shown that AZT slightly down-regulates IL-2 receptor α-expression in PHA-stimulated normal human PBMCs (Viora et al., 1995) . In our hands, AZT down-regulated the expression of CD25 in uninfected as well as in infected cells. However, AZT treatment of infected cultures seems not to be associated specifically with modulation of the α-chain of the IL-2 receptor, although our data do not allow us to exclude this hypothesis completely. Moreover, in infected cells treated with AZT, the expression of HLA-DR was strongly inhibited in comparison with that of infected cells grown in the absence of the drug. Conversely, HLA-DR expression in uninfected cells was not appreciably affected by AZT treatment. Therefore, inhibition of HLA-DR in virus-exposed and AZT-treated cells might be due to a block of virus transmission. It should be taken into account that our results in vitro have implications for a possible application of AZT in vivo. Firstly, our data clearly demonstrate that in bulk culture of human PBMCs AZT can effectively prevent the transmission of HTLV-I when administered at the onset of the infection. Secondly, in our experimental model, it is confirmed that AZT is not effective on already established retroviral infection (Poli et al., 1989 ). This remains a major limitation in the use of this drug, particularly in chronically persistent infections such as those caused by HTLV-I and characterized by vertical cell-to-cell spread of the viral genome. A third implication is that the dose of AZT is important in order to obtain the best results from this drug. In fact, our data indicate the existence of a threshold level under which AZT completely loses its long-term efficacy. At the same time, however, we have shown that it is possible to find doses that maintain the full antiviral action of the drug without causing undesirable cytotoxic effects toward mature lymphoid cells (Styrt et al., 1996) . These considerations should be taken into account particularly in the design of antiviral regimes to treat healthy carriers, or to block virus transmission from HTLV-I-infected mothers to the foetus. Finally, on the basis of our results, a clear indication exists for developing combination therapies in which the strong protective activity of AZT at non-toxic doses against the horizontal cell-to-cell spread of HTLV-I infection could be flanked by a putative second antiviral drug able to affect vertical transmission or to selectively kill cells already infected. 
